Isolation of human platelets from whole blood

This protocol outlines a reliable method for isolating human platelets from whole blood, minimizing activation and preserving functionality. This procedure requires the use of specific buffers and gentle handling techniques to ensure high-quality platelet samples suitable for downstream applications. Researchers can apply this method in studies involving platelet signaling, aggregation, and granule release. The protocol is compatible with techniques such as western blotting, flow cytometry, ELISA, and immunofluorescence. By following the recommended steps and using appropriate inhibitors, you can achieve consistent results while avoiding common pitfalls. This guide is ideal for researchers seeking a reproducible and efficient approach to platelet isolation for both basic and applied research.

Introduction

Platelets play a critical role in hemostasis, inflammation, and cellular signaling. Isolating them from whole blood is essential for studying their function in vitro, and this protocol is optimized for platelets isolated from venous blood. This protocol provides a step-by-step guide for obtaining intact and unactivated platelets using optimized buffers and gentle centrifugation. The method is designed to prevent platelet activation, which can compromise experimental outcomes. It is suitable for a wide range of research applications, including molecular biology, immunology, and pharmacology. This protocol is particularly useful for researchers investigating platelet behavior under various stimuli or assessing the impact of therapeutic agents on platelet function.

Background and principles

Platelets are small, anucleate cell fragments derived from megakaryocytes, crucial for clot formation and immune responses. Their isolation requires careful handling to avoid activation, which alters their morphology and function. This protocol uses anticoagulant buffers like acid citrate dextrose (ACD) and CPD to stabilize platelets and prevent aggregation. Centrifugation steps are optimized to separate platelets from other blood components while maintaining their integrity. The method of platelet separation, such as washing versus direct resuspension, can influence platelet activation state, plasma contamination, and the outcome of subsequent experiments. The inclusion of inhibitors and temperature control further ensures minimal activation. Understanding these principles is key to obtaining high-quality samples for downstream analyses such as protein expression, receptor profiling, and functional assays.

Strong mechanical forces (eg, fast pipetting, vigorous shaking) should be avoided to prevent platelet activation during the procedure. In addition, the platelet inhibitors indicated in the protocol can be used, but other inhibitors exist as well. It is the researcher’s choice to select inhibitors that are most suitable for their studies and experimental goals.

Western blotting, flow cytometry, ELISA, and immunocytochemistry/ immunofluorescence are examples of downstream applications of isolated platelets when investigating cellular and signaling processes within the platelets. Platelet aggregation and adhesion upon stimulation with various agents can be studied, as can the release of granule components upon activation.

The reagents do not need to be sterile unless platelets are used in tissue culture experiments. Store and use all buffers at 4°C unless indicated otherwise.

Required materials

• ACD buffer (acid-citrate-dextrose)

  • 39 mM citric acid, 75 mM sodium citrate, 135 mM dextrose, pH 7.4.
  • Before use, warm up to room temperature and adjust pH if necessary.

• CPD buffer (citrate-phosphate-dextrose)

  • 16 mM citric acid, 90 mM sodium citrate, 16 mM NaH₂PO₄, 142 mM dextrose, pH 7.4.
  • Before use, warm up to room temperature and adjust pH if necessary.

• Platelet wash buffer

  • 10 mM sodium citrate, 150 mM NaCl, 1 mM EDTA, 1% (w/v) dextrose, pH 7.4.
  • Before use, warm up to room temperature and adjust pH if necessary.

• HEP buffer (HEP refers to HEPES in the buffer)

  • 140 mM NaCl, 2.7 mM KCl, 3.8 mM HEPES, 5 mM EGTA, pH 7.4.
  • Before use, warm up to room temperature and adjust pH if necessary.

• Tyrode's buffer

  • 134 mM NaCl, 12 mM NaHCO₃, 2.9 mM KCl, 0.34 mM Na₂HPO₄, 1 mM MgCl₂, 10 mM HEPES, pH 7.4.
  • Depending on the experiment, warm the buffer up to room temperature or keep it on ice before use.

• 2X platelet lysis buffer

  • 2% NP40, 30 mM HEPES, 150 mM NaCl, 2 mM EDTA, pH 7.4.

Notes on blood collection

• Many drugs are known to interfere with platelet studies and platelet function. It is important to ensure that potential blood donors have not taken such medication (eg, antihistamines, aspirin, and non-steroidal anti-inflammatory medication) two weeks prior to the blood draw.
• Platelets are recommended to be handled and stored in polypropylene, polyethylene, or polycarbonate labware.
• Blood and intact platelets should preferentially be handled at room temperature or 37°C.
• Blood is a bodily fluid and should be considered biohazardous. Protective equipment should be worn at all times, and blood should be disposed of according to the regulations of the researcher's institution.

Stage 1 - Blood fractionation

The first step of this procedure includes obtaining the whole blood and preparing PRP by centrifugation. The centrifugation conditions can vary widely (eg, from 800 x g for 5 min to 100 x g for 20 min), but give consistently good separations.

A phlebotomist should draw blood into a Becton Dickinson Vacutainer^® (containing ACD, yellow cap) or into a plastic syringe containing 1/10 volume of CPD buffer. The volume of blood needed depends on the experiment. A volume of 40–45 mL of blood results in an average of 1–3 × 10⁹ platelets. The platelet number can vary depending on the individual from whom the blood is drawn.

Steps

Mix gently during and after blood collection by slowly inverting the Vacutainer^® or syringe.

If a Vacutainer^® is not being used, transfer blood into a plastic tube suitable for centrifugation by using a plastic transfer pipette (wide orifice).

Spin at 200 x g for 20 min at room temperature (with no brake applied).

After the spin, three distinct layers can be observed:

• Bottom layer: Red blood cells (accounting for 50–80% of the total volume)
• Middle layer: Very thin band of white blood cells (also called "buffy coat")
• Top layer: Straw-colored PRP

Figure 1. Schematic representation of blood constituents

Stage 2 - Platelet isolation

Steps

Transfer two thirds of the PRP from the blood fractionation into a new plastic tube using a transfer pipette (wide orifice).

Add HEP buffer at a 1:1 ratio (v/v). Include prostaglandin E1 (PGE1, 1 µM final concentration) to prevent platelet activation.

Mix very gently by inverting the tube slowly.

Spin at 100 x g for 15–20 min at room temperature (with no brake applied) to pellet contaminating red and white blood cells.

Transfer the supernatant into new plastic tube using a transfer pipette (wide orifice).

Pellet platelets by centrifugation at 800 x g for 15–20 min at room temperature (with no brake applied). Discard the supernatant.

Rinse the platelet pellet with platelet wash buffer (without resuspension in order to avoid unnecessary platelet activation) by gently adding wash buffer and removing it slowly with a pipette.

Repeat once.

Carefully and slowly resuspend the pellet in Tyrode's buffer containing 5 mM glucose and freshly added BSA (3 mg/mL) using a transfer pipette (wide orifice).

Release the buffer slowly along the tube wall and minimize the amount of agitation.

Count the platelets (eg, using a hemocytometer, semi-automated Coulter-type counters, or an electronic particle analyzer).

Adjust the platelet concentration as needed with Tyrode's buffer.

Platelet activation and agonists

Platelet activation is a fundamental process in hemostasis, where platelets respond to vascular injury by adhering to the site, aggregating with one another, and releasing granule contents that promote clot formation. In the context of laboratory research, maintaining platelets in a quiescent state during isolation is essential for accurately studying platelet function and responsiveness. The isolation of human platelets from whole blood requires meticulous technique to prevent premature activation, which can compromise experimental results.

A key step in this process is preparing platelet-rich plasma (PRP), a concentrate of platelets from whole blood that serves as the starting material for many platelet studies. PRP is rich in growth factors and widely used in research and clinical applications. Using ACD as an anticoagulant during isolation helps stabilize platelets and prevent activation. Additionally, employing a transfer pipette with a wide orifice minimizes shear stress, further reducing the risk of activating platelets.

To ensure the isolation of quiescent platelets, it is critical to avoid strong mechanical forces such as fast pipetting or vigorous shaking. These actions can trigger platelet activation, leading to unwanted aggregation and the release of granule contents. The protocol describes the use of platelet inhibitors, such as prostaglandin E1 (PGE1), to prevent activation during key steps. However, other platelet inhibitors exist as well, and researchers should select the most appropriate agents based on their specific experimental needs.

Platelet concentration is another important consideration. For most platelet studies, a final concentration of 1x10⁹ platelets/mL is optimal for assessing platelet aggregation, activation, and function. Platelet agonists., including ADP, thrombin, and collagen, are commonly used in functional assays to stimulate platelet activation and aggregation. For example, the addition of thrombin or U46619 can induce robust platelet aggregation, resulting in the formation of a dense clot, which is useful for studying the mechanisms of platelet function.

Throughout the isolation procedure, you should handle platelet samples carefully, using transfer pipettes to move platelet suspensions between tubes gently. Resuspend the platelet pellet after centrifugation in a buffer such as Modified Tyrode’s buffer, with the pH carefully adjusted to 7.4, and incubate the suspension at room temperature, typically for 20 min, to allow the platelets to rest and become quiescent before further experimentation.

The process of isolating platelets from whole blood involves several carefully controlled stages, beginning with stage 1 blood fractionation to separate red blood cells, white blood cells, and platelets. The buffy coat layer containing platelets is isolated and further purified through additional centrifugation steps. The resulting platelet suspension is adjusted to the desired final concentration and is ready for use in a variety of platelet studies, including aggregation, signaling, and functional assays.

Adhering to best practices in blood collection and platelet isolation is essential for obtaining high-quality, uncontaminated, and functionally intact platelet samples. Using aseptic techniques, handling samples gently, and incorporating platelet inhibitors where appropriate all contribute to the successful isolation of human platelets from whole blood. By following these guidelines, researchers can reliably study platelet activation, aggregation, and function in a controlled laboratory setting.

Comparison to other methods

Compared to density gradient centrifugation or commercial kits, this protocol offers a cost-effective and customizable approach to platelet isolation. While kits may provide convenience, they often lack flexibility in buffer composition and inhibitor selection. Gradient methods can yield high purity but may activate platelets due to mechanical stress. Such activation can result in the presence of activated platelets, which may release extracellular vesicles and alter experimental outcomes. The above protocol emphasizes gentle handling and buffer optimization, making it suitable for sensitive applications. It also allows researchers to tailor the protocol to specific experimental needs, such as adjusting buffer pH or selecting alternative inhibitors. This adaptability makes it a preferred choice for many labs.

Applications

Isolated platelets are valuable for a wide range of research applications. This protocol supports studies in platelet signaling, aggregation, and secretion. Common downstream techniques include western blotting, flow cytometry, ELISA, and immunofluorescence. Researchers can investigate receptor expression, intracellular pathways, and platelet responses to pharmacological agents. The method also facilitates studies on platelet adhesion and granule release under various stimuli. Additionally, it is suitable for translational research, including biomarker discovery and drug testing. This protocol ensures reliable data across diverse experimental platforms by preserving platelet functionality.

Limitations

While effective, this protocol has some limitations. Platelet activation can still occur if handling is too vigorous or buffers are improperly prepared. The method requires access to fresh human blood, which ethical or logistical constraints may restrict. It also demands careful temperature control and buffer pH adjustment, which can introduce variability. Additionally, the protocol may not be suitable for isolating platelets from patients with certain hematological conditions. Researchers must also ensure donors have not taken medications that affect platelet function, such as NSAIDs or antihistamines, prior to blood collection.

Troubleshooting

Common issues in platelet isolation include low yield, activation, and contamination. To improve yield, ensure centrifugation speeds and times are accurate. Verify buffer pH and temperature if activation occurs, and avoid vigorous pipetting. Use recommended inhibitors and handle samples gently. Contamination with leukocytes or erythrocytes may result from improper layering or centrifugation; adjust technique accordingly. If platelet function is compromised, check donor medication history and buffer freshness. Always prepare buffers at room temperature and store at 4°C unless otherwise specified. Regular calibration of equipment and adherence to protocol steps can significantly enhance reproducibility.